近日，105家券商2024年文化建设年报在中国证券业协会网站公布。 （图：国泰海通、东吴证券文化建设年报内页） （图：中金公司、华泰证券、广发证券、中国银河证券文化建设年报内页） 党建引领仍是各内资券商文化建设年报最鲜明的共性之一，不少券商创新了党建形式，打造了特色党建品牌。例如，中泰证券打造了"红心如磐"党建品牌；华安证 券打造了"赤金"党建品牌；华源证券探索"智慧党建云+源文化+国企担当"融合发展模式；国泰海通证券则打造"融·党建"活动室特色宣传教育阵地，创新学习方式、 凝聚宣讲力量，推动党的创新理论深入一线、深入群众、深入人心。 打造廉洁文化，加强员工职业道德建设也是诸多券商近一年文化建设工作的重点之一。2024年9月，中国证券业协会修订发布了新版《证券从业人员职业道德准 则》，旨在引导证券从业人员珍惜职业声誉、恪守职业道德。 自2019年证券基金行业文化建设拉开序幕以来，今年已是各券商第四年提交文化建设年报。相比前三年，今年券商提交的文化建设年报更为体系化，案例更为丰 富，年报排版与设计精美度也直线上升。 从内容与形式来看，券商文化建设工作"卷"出新高度，一些券商新创设了党建、廉洁从业等子品牌，通过打 ...

Group 1 - The core viewpoint is that the valuation enhancement logic of the gold and jewelry industry will continue to unfold in 2024, as the industry enters a phase of clearing and upgrading [1] - Leading companies are shifting from store expansion strategies to improving efficiency at individual stores, forming a synergy with franchisees to promote high-margin products [1] - Differentiated products are driving gold and jewelry companies to transition from "channel brands" to "consumer brands," indicating a strong focus on product strength and the ability to capture consumer demand [1]

Core Viewpoint - The overall sensitivity of deposit scale to the reduction in deposit interest rates is low under the trend of low interest rates [1] Group 1: Deposit Scale and Interest Rate Sensitivity - The deposit scale is not sensitive to the reduction in non-interbank deposit rates, primarily due to the manual interest compensation rectification in April 2024, which caused a short-term outflow of deposits to asset management products [2] - Despite several rounds of deposit rate cuts since 2022, the year-on-year growth rate of personal and corporate deposits has aligned with the growth rate of broad money supply, with the proportion of deposits in broad money supply rising from around 48% to a peak of 52% by March 2024 [2][3] - The proportion of deposits in low-risk preference funds has shown a slight decline from a peak of 79.3% in March 2023, indicating manageable outflow pressure [2] Group 2: Impact of Deposit Rate Cuts - The disturbances caused by deposit rate cuts on fund outflows were not significant before 2024, but became more pronounced afterward due to increased price comparison willingness in a low-interest environment [3] - Following the deposit rate cuts in July and October 2024, there was a noticeable decline in the year-on-year growth of large bank deposits, indicating a shift towards asset management products [3][4] - The current round of deposit rate cuts is not expected to lead to a significant tightening of the funding environment, as the year-on-year growth of deposits has remained stable despite the cuts [4] Group 3: Future Expectations - The attractiveness of asset management products relative to deposits is expected to decrease due to the ongoing adjustments in performance benchmarks and the gradual implementation of net value rectification [4] - The company anticipates that the ticket interest strategy will continue to prevail, with high-grade short-duration credit bonds likely to benefit from some funds flowing from deposits to asset management products [4]

国泰海通证券股份有限公司 关于无锡芯朋微电子股份有限公司 关于差异化权益分派特殊除权除息的核查意见 国泰海通证券股份有限公司（以下简称"保荐人"、"国泰海通"）作为正在 履行无锡芯朋微电子股份有限公司（以下简称"芯朋微"、"公司"）持续督导工 作的保荐人，根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板 股票上市规则》 根据《上市公司股份回购规则》等有关规定，上市公司回购专用证券账户中 的股份，不享有利润分配、公积金转增股本的权利。因此，公司回购专用证券账 户中的股份将不参与公司本次利润分配、公积金转增股本，故申请 2024 年度权 益分配实施差异化权益分派。具体情况如下： 一、差异化分红的原因 以集中竞价交易方式回购公司股份方案的议案》，同意公司以超募资金通过上海 证券交易所交易系统以集中竞价交易方式回购公司已发行的部分人民币普通股 股票。回购的股份将在未来适宜时机全部用于员工持股计划或股权激励，回购价 格不超过 151.70 元/股（含），回购资金总额不低于人民币 5,500 万元（含），不 超过人民币 11,000 万元（含），回购期限自公司董事会审议通过本次回购方案之 日起 6 个月内。截至 ...

Core Insights - The overall sensitivity of deposit scale to the reduction of deposit rates is low, indicating a strong willingness among individuals and businesses to allocate funds to bank deposits despite rate cuts [1][10] - The shift of deposits from the banking system to asset management products is primarily attributed to the manual interest compensation rectification in April 2024, which had a short-term impact but began to stabilize by July of the same year [1][10] - The proportion of personal and corporate deposits in the broad money supply has increased from approximately 48% to 52% by March 2024, reflecting a robust demand for bank deposits [1][10] Deposit Rate Adjustments - The reduction in deposit rates in July and October 2024 led to a noticeable decline in the year-on-year growth of large bank deposits, dropping from 5.8 trillion yuan to 5.2 trillion yuan and from 5.0 trillion yuan to 4.8 trillion yuan respectively [3] - The asset management product scale saw a rebound, with a shift from a year-on-year decrease of 629.5 billion yuan in August 2024 to a slight increase of 10 billion yuan, and a similar trend was observed in November 2024 [3] Deposit Growth Trends - Large banks' personal and corporate deposit year-on-year growth fluctuated, with notable increases and decreases observed in various months, indicating a dynamic response to interest rate changes [5] - The year-on-year growth of deposits in small and medium-sized banks also showed variability, with a peak growth of 81.56 billion yuan followed by a decrease of 25.29 billion yuan [5] Market Reactions - The bond market typically reacts in advance to expectations of deposit rate cuts, with rates generally declining before the official announcement, although the actual impact on market trends remains limited [10] - Following the last three deposit rate cuts, the yields on various bonds, including government bonds and credit bonds, generally trended downward over the subsequent trading days [10] Future Outlook - The current round of deposit rate cuts is expected to have a limited impact on the outflow of funds, with the probability of a return to a tight liquidity situation similar to the first quarter of the year being low [10] - The attractiveness of asset management products is anticipated to decrease due to ongoing adjustments in performance benchmarks, which may lead to a shift of funds back to deposits [10]

Group 1 - The event "Rational Investment Companion" focused on the company Zhifei Biological Products Co., Ltd. (300122), which is a component of the ChiNext 50 Index, aimed at enhancing investor services and promoting investment quality [2][3] - Zhifei Biological, established in 2002, is a comprehensive biopharmaceutical company engaged in the research, production, sales, and distribution of vaccines and biological products, and was the first private vaccine company listed on the ChiNext in September 2010 [3][4] - The company’s main products include various vaccines such as recombinant COVID-19 protein vaccine, tuberculosis vaccines, and meningococcal polysaccharide vaccines, with a recent collaboration with GSK for the exclusive distribution of a recombinant shingles vaccine [4][5] Group 2 - The event agenda includes a tour of Zhifei Biological's exhibition hall, an introduction to the Shenzhen Stock Exchange, sharing of ETF investment strategies, discussion on index investment value, and interactive communication with investors [4][6] - The company operates under the mission of "preventing diseases before they occur and treating existing diseases," aiming to build a world-class biopharmaceutical enterprise [3][4]

Core Insights - The digital transformation in wealth management is centered around brokers enhancing their app platforms to create a new online service ecosystem [1][4] - In April, the total active users of securities apps reached 167 million, marking a year-on-year increase of 14.29% [2][4] - The trend of upgrading app functionalities, particularly through AI technologies, is becoming a focal point for brokers [3][4] Group 1: Market Activity - The A-share market has seen increased activity, with 9.4 million new accounts opened in the first four months of the year, a year-on-year growth of 31.51% [2] - In April, 11 brokers had apps with over 5 million monthly active users, with Huatai Securities' "Zhangle Wealth" leading at 11.22 million [2][4] - Despite a slight month-on-month decline of 2.7% in active users, the year-on-year growth remains strong [2] Group 2: Technological Advancements - Brokers are focusing on integrating AI and other advanced technologies into their app functionalities to enhance service quality and efficiency [3][4] - Recent updates to apps include features like intelligent investment tools, market tracking, and ETF investment options [3] - The use of AI models is seen as essential for brokers to meet diverse investor needs and improve resource allocation efficiency [4] Group 3: Competitive Landscape - The competition among brokers is intensifying, with a need to differentiate through unique features and services [5] - Brokers are encouraged to leverage user behavior data and AI algorithms to create customized investment solutions [5] - Future developments in broker apps are expected to focus on smart, scenario-based, and diversified services to enhance user engagement [5]

Core Viewpoint - The report outlines the continuous sponsorship and supervision activities conducted by Guotai Junan Securities for Shaanxi Sry New Materials Co., Ltd. following its IPO, emphasizing compliance with regulations and the company's operational performance. Group 1: Continuous Supervision Activities - The company issued 40.01 million shares at a price of RMB 10.48 per share, raising a total of RMB 419.30 million, with a net amount of RMB 356.91 million after deducting issuance costs [1]. - Guotai Junan Securities has been appointed as the continuous sponsor from March 16, 2022, to December 31, 2025, conducting regular communications, site inspections, and due diligence [1][2]. - The sponsor has assisted the company in establishing internal systems and decision-making processes to comply with legal and regulatory requirements [1][2]. Group 2: Information Disclosure and Compliance - The sponsor reviewed the company's information disclosure documents, ensuring compliance with relevant regulations and confirming that disclosures were accurate and timely [9]. - During the supervision period, the company and its major stakeholders did not fail to fulfill any commitments [2][6]. - The company has been advised to maintain transparency and avoid concealing important information [1][2]. Group 3: Financial Performance and Key Indicators - The company's revenue for 2024 is reported at approximately RMB 1.33 billion, reflecting a 12.73% increase from the previous year [20]. - The net profit attributable to shareholders increased by 26.88%, driven by revenue growth and improved sales structure [22]. - The company's total assets reached approximately RMB 2.13 billion, marking a 24.39% increase compared to the previous year [20]. Group 4: Research and Development - The company invested RMB 68.83 million in R&D, representing 5.18% of its revenue, which is an increase from 5.04% in the previous year [22]. - The company has developed new products and technologies, including high-performance copper alloys for liquid rocket engines and components [22][24]. - The R&D team, led by nine core technical personnel, has established partnerships with aerospace institutions to enhance technological capabilities [11][22]. Group 5: Market Risks and Challenges - The company faces risks related to technological advancements in the new materials industry, which require continuous R&D investment to maintain competitive advantages [10][17]. - Potential market disruptions may arise from the introduction of new materials and technologies that could replace existing products [17][18]. - The company is also exposed to risks from fluctuations in raw material prices, particularly copper, which significantly impacts production costs [14][16].

国泰海通证券股份有限公司 关于用友汽车信息科技（上海）股份有限公司 差异化权益分派特殊除权除息事项的核查意见 《上海证券交易所科创板股票上公规则》 《上海证券交 （ 易所上公公司自律监管指引第 11 号——持续督导》 《上海证券交易所科创板上公 （ 公司自律监管指引第 7 号——回购股份》等有关法律、法规的规定，对友车科技 差异化权益分派特殊除权除息事项进行了审慎核查，具体情况如下： 一、本次差异化权益分派的原因 国泰海通证券股份有限公司（以下简称"国泰海通"、"保荐人"）作为用友 汽车信息科技（上海）股份有限公司（ （以下简称（ "公司"、 "（ 上公公司"、 "友车科 技"）首次公开发行股票并在科创板上公持续督导工作的保荐人，根据《证券发 行上公保荐业务管理办法》 根据公司 2024 年年度股东大会审议通过的《关于 2024 年度利润分配预案的 议案》，公司拟向全体股东每 10 股派发现金红利 5.00 元（含税），不送红股，不 进行资本公积转增股本。公司通过回购专用账户所持有的本公司股份不参与本次 利润分配。截至 2025 年 3 月 27 日，公司总股本 144,317,400 股，扣除回购专用 证券 ...

Core Viewpoint - The company, Maiwei (Shanghai) Biotechnology Co., Ltd., has faced challenges in its product sales, particularly with its flagship products, Kunmaikang and Maiweijian, due to market competition and regulatory hurdles, but is implementing strategic adjustments to improve performance and expand market access [1][2][4]. Group 1: Company Performance - In 2024, the company achieved a revenue of 200 million RMB, a year-on-year increase, but faced a significant decline in the shipment of Kunmaikang, which dropped by 66.61% to 48,821 units [1][2]. - The sales revenue for Maiweijian reached 14,459.20 million RMB in 2024, with a gross profit margin of 82.89% [2][3]. - The overall gross profit for the company increased from 4,075.41 million RMB in 2023 to 11,984.65 million RMB in 2024, with a gross profit margin decrease from 96.83% to 82.89% [3][4]. Group 2: Product Analysis - Kunmaikang, a biosimilar to Humira, has seen a decline in shipment volume due to intense market competition and regulatory challenges, with eight similar products already approved in China [5][6]. - Maiweijian, a biosimilar to Xgeva, has been gradually gaining market access, with 75 hospitals approved by the end of 2024, but its market entry has been slower compared to the original drug [10][11]. - The company plans to expand the indications for Maiweijian to include SREs, which could enhance its market potential [12][20]. Group 3: Strategic Adjustments - The company is optimizing its regional operational model to improve efficiency and resource allocation, transitioning from self-operated sales to cooperative models in underperforming areas [8][9]. - A focus on enhancing marketing strategies and academic promotion is underway to improve brand recognition and market penetration for Kunmaikang [9][10]. - The company is actively pursuing international collaborations and expanding its product pipeline, with several products in advanced clinical stages expected to launch in the next few years [21][22][23].